Collaboration between pharmaceutical industry leaders On January 19, 2026, SCHOTT Pharma (a specialist in drug containment) and SHL Medical (a manufacturer of delivery systems) announced the pre-validation of SCHOTT TOPPAC polymer cartridges with SHL Medical’s Maggie large-volume autoinjector platform. This represents a significant milestone in providing safe, home-use medical devices for large-volume biologic therapies.
Advantages of Polymer Materials The SCHOTT TOPPAC polymer cartridge is made from Cyclic Olefin Copolymer (COC), offering technical characteristics ideal for modern medical therapies:
-
Containment capabilities: Suitable for highly sensitive biologics, cell and gene therapies, and biosimilars.
-
Durability: Break-resistant, lightweight, and maintains stability even during deep-temperature storage.
-
Standardization: Meets ISO-standardized dimensions and the global ready-to-use (RTU) standard of the SCHOTT iQ platform.
Fully pre-validated system Joint assessments between the two companies have confirmed complete dimensional and functional compatibility between the cartridges and the injection devices:
-
The 3 ml cartridge is compatible with the Maggie 3.0 ml platform.
-
The 5 ml cartridge is compatible with the Maggie 5.0 ml platform. This pre-validation de-risks the process for pharmaceutical companies and accelerates time-to-market while offering patients a convenient solution for self-administration at home.